Inventor · disambiguated record
Stanley R. Riddell
Also filed as: RIDDELL STANLEY · RIDDELL STANLEY R
28 granted patents·26 pending applications·992 citations·filing 1994–2025
96Inventor score
Files withHUTCHINSON FRED CANCER RES25FRED HUTCHINSON CANCER CENTER14JUNO THERAPEUTICS INC6RIDDELL STANLEY R3HOPE CITY2
Top patents by PatentIndex Score
54 records- 0197US10736918B2Method and compositions for cellular immunotherapyHUTCHINSON FRED CANCER RES·Filed 2017·Granted Aug 11, 2020·24 cites·30 claims
- 0297US6040177AHigh efficiency transduction of T lymphocytes using rapid expansion methods ("REM")HUTCHINSON FRED CANCER RES·Filed 1996·Granted Mar 21, 2000·593 cites·24 claims
- 0396US10780118B2Method and compositions for cellular immunotherapyHUTCHINSON FRED CANCER RES·Filed 2013·Granted Sep 22, 2020·21 cites·37 claims
- 0496US9163258B2Method for the treatment of obesityRIDDELL STANLEY R·Filed 2011·Granted Oct 20, 2015·41 cites·13 claims
- 0595US10869889B2Method and compositions for cellular immunotherapyHUTCHINSON FRED CANCER RES·Filed 2019·Granted Dec 22, 2020·8 cites·18 claims
- 0695US5827642ARapid expansion method ("REM") for in vitro propagation of T lymphocytesHUTCHINSON FRED CANCER RES·Filed 1994·Granted Oct 27, 1998·235 cites·11 claims
- 0792US10968275B2Anti-ROR1 antibodies and uses thereofHUTCHINSON FRED CANCER RES·Filed 2017·Granted Apr 6, 2021·17 cites·19 claims
- 0889US11065278B2Method and compositions for cellular immunotherapyHUTCHINSON FRED CANCER RES·Filed 2018·Granted Jul 20, 2021·3 cites·11 claims
- 0989US9987308B2Method and compositions for cellular immunotherapyRIDDELL STANLEY R·Filed 2012·Granted Jun 5, 2018·16 cites·31 claims
- 1088US10828352B2Compositions and methods for boosting the efficacy of adoptive cellular immunotherapyHUTCHINSON FRED CANCER RES·Filed 2015·Granted Nov 10, 2020·6 cites·31 claims
- 1187US12193994B2Combination of a cell therapy and a gamma secretase inhibitorJUNO THERAPEUTICS INC·Filed 2018·Granted Jan 14, 2025·4 cites·32 claims
- 1287US10494434B2Tagged chimeric effector molecules and receptors thereofHUTCHINSON FRED CANCER RES·Filed 2014·Granted Dec 3, 2019·10 cites·31 claims
- 1386US11046766B2Tagged chimeric effector molecules and receptors thereofHUTCHINSON FRED CANCER RES·Filed 2019·Granted Jun 29, 2021·2 cites·34 claims
- 1485US10653756B2Identification of CD8+ T cells that are CD161hi and/or IL18R(α)hi and have rapid drug efflux capacityHUTCHINSON FRED CANCER RES·Filed 2018·Granted May 19, 2020·2 cites·15 claims
- 1585US2024390491A1Method and compositions for cellular immunotherapyFRED HUTCHINSON CANCER CENTER·Filed 2024·Application pending·0 cites
- 1683US11815514B2Methods and compositions related to toxicity associated with cell therapyJUNO THERAPEUTICS INC·Filed 2016·Granted Nov 14, 2023·2 cites·31 claims
- 1783US10400215B2Adoptive transfer of CD8+ T cell clones derived from central memory cellsHOPE CITY·Filed 2014·Granted Sep 3, 2019·3 cites·16 claims
- 1882US11932691B2Anti-ROR1 antibodies and uses thereofFRED HUTCHINSON CANCER CENTER·Filed 2021·Granted Mar 19, 2024·1 cites·33 claims
- 1982US10968431B2Adoptive transfer of CD8+ T cell clones derived from central memory cellsHOPE CITY·Filed 2019·Granted Apr 6, 2021·1 cites·21 claims
- 2078US2024352119A1Anti-ror1 antibodies and uses thereofFRED HUTCHINSON CANCER CENTER·Filed 2024·Application pending·0 cites
- 2173US2025090542A1Combination of a cell therapy and a gamma secretase inhibitorJUNO THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2272US2024103012A1Methods and compositions related to toxicity associated with cell therapyJUNO THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2371US11993652B2Tagged chimeric effector molecules and receptors thereofFRED HUTCHINSON CANCER CENTER·Filed 2021·Granted May 28, 2024·0 cites·25 claims
- 2471US2021052649A1Method and compositions for cellular immunotherapyHUTCHINSON FRED CANCER RES·Filed 2020·Application pending·0 cites
- 2570US9090875B2Identifcation of CD8+ T cells that are CD161hi and/or IL18Rαhi and have rapid drug efflux capacityTURTLE CAMERON J·Filed 2009·Granted Jul 28, 2015·2 cites·14 claims
- 2669US9931384B2Identification of CD8+ T cells that are CD161hi and/or IL18Rαhi and have rapid drug efflux capacityHUTCHINSON FRED CANCER RES·Filed 2015·Granted Apr 3, 2018·1 cites·20 claims
- 2766US2024166758A1Combination therapies for treatment of bcma-related cancers and autoimmune disordersFRED HUTCHINSON CANCER CENTER·Filed 2023·Application pending·0 cites
- 2866US2023003733A1Biomarkers and uses thereof for selecting immunotherapy interventionFRED HUTCHINSON CANCER CENTER·Filed 2022·Application pending·0 cites
- 2963US2022204935A1Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereofHUTCHINSON FRED CANCER RES·Filed 2021·Application pending·0 cites
- 3061US2008131415A1Adoptive transfer of cd8 + t cell clones derived from central memory cellsRIDDELL STANLEY R·Filed 2007·Application pending·0 cites
- 3158US2025197471A1Methods for the treatment of b cell malignancies using adoptive cell therapyJUNO THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3257US11845803B2Combination therapies for treatment of BCMA-related cancers and autoimmune disordersFRED HUTCHINSON CANCER CENTER·Filed 2018·Granted Dec 19, 2023·0 cites·33 claims
- 3357US11397183B2Biomarkers and uses thereof for selecting immunotherapy interventionFRED HUTCHINSON CANCER CENTER·Filed 2018·Granted Jul 26, 2022·0 cites·21 claims
- 3455US2025236915A1Cd4+ t cell markers, compositions, and methods for cancerFRED HUTCHINSON CANCER CENTER·Filed 2023·Application pending·0 cites
- 3554US2022401537A1Chimeric receptor proteins and uses thereofHUTCHINSON FRED CANCER RES·Filed 2020·Application pending·0 cites
- 3654US2024165232A1Chimeric receptor proteins and uses thereofHUTCHINSON FRED CANCER RES·Filed 2019·Application pending·0 cites
- 3753US2021292711A1Methods and compositions for adoptive t cell therapy incorporating induced notch signalingHUTCHINSON FRED CANCER RES·Filed 2019·Application pending·0 cites
- 3852US12350312B2Methods for improving adoptive cell therapyFRED HUTCHINSON CANCER CENTER·Filed 2018·Granted Jul 8, 2025·0 cites·47 claims
- 3952US2021079061A1Compositions and methods for cellular immunotherapyHUTCHINSON FRED CANCER RES·Filed 2019·Application pending·0 cites
- 4051US2021145882A1Methods for adoptive cell therapy targeting ror1HUTCHINSON FRED CANCER RES·Filed 2019·Application pending·0 cites
- 4151US2016095883A1Method for the treatment of obesityDEPT OF HEALTH AND HUMAN SERVICES THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY·Filed 2015·Application pending·0 cites
- 4249US2022218752A1Lockr-mediated recruitment of car t cellsUNIV WASHINGTON·Filed 2020·Application pending·0 cites
- 4348US2021023132A1Strep-tag specific chimeric receptors and uses thereofHUTCHINSON FRED CANCER RES·Filed 2018·Application pending·0 cites
- 4448US2018355318A1Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereofHUTCHINSON FRED CANCER RES·Filed 2016·Application pending·0 cites
- 4547US12351618B2Engineered trimeric CD70 proteins and uses thereofFRED HUTCHINSON CANCER CENTER·Filed 2020·Granted Jul 8, 2025·0 cites·18 claims
- 4647US2021069241A1Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpressionHUTCHINSON FRED CANCER RES·Filed 2018·Application pending·0 cites
- 4746US2021340201A1Immunotherapy targeting kras or her2 antigensHUTCHINSON FRED CANCER RES·Filed 2019·Application pending·0 cites
- 4846US2020262894A1Strep-tag specific binding proteins and uses thereofHUTCHINSON FRED CANCER RES·Filed 2018·Application pending·0 cites
- 4945US2023158164A1Method for enhancing cellular immunotherapyNEKTAR THERAPEUTICS·Filed 2020·Application pending·0 cites
- 5045US2020016199A1Methods for the treatment of b cell malignancies using adoptive cell therapyJUNO THERAPEUTICS INC·Filed 2017·Application pending·0 cites
Showing the top 50 of 54 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →